Detalhe da pesquisa
1.
Phase 1/1b study of azacitidine and hedgehog pathway inhibitor sonidegib in patients with myeloid neoplasms.
Cancer
; 129(15): 2321-2330, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37042080
2.
A phase II study of combination daunorubicin, cytarabine (Ara-c), and nilotinib (TAsigna) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expression.
Am J Hematol
; 98(3): 472-480, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36625066
3.
The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.
BMC Cancer
; 22(1): 1013, 2022 Sep 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36153475
4.
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.
Blood
; 131(24): 2661-2669, 2018 06 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-29724899
5.
Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations.
Blood
; 130(14): 1644-1648, 2017 10 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28801450
6.
E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases.
Invest New Drugs
; 37(4): 636-645, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30264293
7.
Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: results of a phase 1 study.
Br J Cancer
; 118(12): 1580-1585, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29867224
8.
Living with Cancer: an Educational Intervention in Cancer Patients Can Improve Patient-Reported Knowledge Deficit.
J Cancer Educ
; 33(3): 653-659, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27730534
9.
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.
Lancet Oncol
; 18(10): 1317-1326, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28844816
10.
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
Lancet Oncol
; 18(8): 1061-1075, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28645776
11.
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.
Blood
; 125(12): 1857-65, 2015 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-25624319
12.
NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017.
J Natl Compr Canc Netw
; 14(12): 1505-1512, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27956535
13.
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.
Lancet Oncol
; 16(9): 1099-1110, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26296954
14.
Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.
Invest New Drugs
; 33(4): 870-80, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25933833
15.
Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.
Haematologica
; 100(9): 1172-9, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26022709
16.
An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.
Haematologica
; 100(9): 1117-30, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26341525
17.
RNAi screening of the kinome with cytarabine in leukemias.
Blood
; 119(12): 2863-72, 2012 Mar 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-22267604
18.
CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo.
Haematologica
; 99(4): 688-96, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24179152
19.
Effect of selection of QTc formula on eligibility of cancer patients for phase I clinical trials.
Invest New Drugs
; 31(4): 1056-65, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23242862
20.
Emerging drugs for polycythemia vera.
Expert Opin Emerg Drugs
; 18(3): 393-404, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23968379